Please login to the form below

Not currently logged in


This page shows the latest thalidomide news and features for those working in and with pharma, biotech and healthcare.

Celgene reaches $9bn agreement to buy Juno

Celgene reaches $9bn agreement to buy Juno

Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation

Latest news

More from news
Approximately 3 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....